We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




First of Its Kind Technology Detects Glucose in Human Saliva

By LabMedica International staff writers
Posted on 30 Nov 2023

Blood tests are vital for assessing health, but they often involve uncomfortable procedures, including frequent finger pricks or blood draws by a phlebotomist. More...

Saliva, which shares many biomarkers with blood, has been considered as an alternative for monitoring health indicators like glucose levels. Traditional analysis of saliva for small molecules often requires lab equipment. Now, a new device capable of detecting glucose and adenosine monophosphate (AMP) in saliva with high sensitivity could simplify home health monitoring and eliminate the discomfort of traditional methods.

At the Université de Sherbrooke in Québec, Canada, researchers have adapted electrochemical aptamer-based (E-AB) biosensors, previously used for testing blood samples, to work with saliva. These biosensors generate an electrochemical signal when a custom-designed DNA or RNA aptamer binds to a specific target molecule. Focusing on glucose and AMP—a biomarker linked to gum disease—the team modified existing DNA aptamers to enhance their sensitivity and mounted them on gold electrodes to create the E-AB biosensors. Saliva samples were gathered from participants and combined for testing. The innovative aspect of this approach lies in its simplicity: the biosensors can be directly immersed in saliva without any additional preparation or reagents, making it feasible for at-home patient use.

The researchers observed that their devices could deliver results in just 30 seconds, remained effective in pure saliva for up to three days, and maintained their sensitivity for a week with proper washing after each use. The glucose sensor demonstrated high specificity for its target, and both AMP and glucose sensors could detect these biomarkers at concentrations lower than those usually present in saliva. This breakthrough, particularly in glucose detection in human saliva, holds promise for making health monitoring less invasive and more manageable for individuals with chronic conditions like diabetes.

Related Links:
Université de Sherbrooke


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.